Vabysmo (faricimab) is the only bispecific antibody registered with the Australian Register of Therapeutic Goods and listed on the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and macular oedema secondary to retinal vein occlusion (RVO).1-3
This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After at least three-weekly initial loading doses for RVO or four initial loading doses for nAMD and DMO, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes.1,4,5
Contact: Roche Account Manager
Please review the Product Information before prescribing, available at: roche-australia.com/solutions/pharma-solutions/vabysmo. Vabysmo ▼vials and prefilled syringe are listed on the PBS for nAMD, DMO, and RVO. Refer to PBS Schedule for full authority information.
▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems. Prepared May 2026.
M-AU-00005206.
References
- Vabysmo Approved Product Information. Available at roche-australia.com/productinfo/vabysmo.
- Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods. Available at: tga.gov.au/resources/artg [accessed February 2025].
- Department of Health. Pharmaceutical Benefits Scheme. Available at pbs.gov.au.
- Heier J, et al. Lancet. 2022;399:729-740. doi: 10.1016/S0140-6736(22)00010-1.
- Wykoff C, et al. Lancet. 2022;399:741-755. doi: 10.1016/S0140-6736(22)00018-6.
